abstract |
The present invention provides compositions, methods and assays for treating inflammation and / or autoimmune diseases and / or graft rejection using anti-alpha beta TCR antibodies and antibody fragments. Anti-alpha beta TCR antibodies are antibodies that bind to alpha beta TCR. Anti-alpha beta TCR antibodies produced by hybridoma TOL101 MCB are also provided. Methods of treating inflammatory diseases, autoimmune diseases and tissue graft rejection using therapeutic dosing regimens of anti-alpha beta TCR antibodies and antibody fragments thereof and methods of upregulating Treg T-cells are also provided. |